Table 4 Serological response to RSV in BALB/c mice following two immunizations with 10 μg of selected mRNA/LNP or protein vaccines.

From: Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

  Prefusion F ELISA GMT (95% CI)a Postfusion F ELISA GMT (95% CI)a RSV-A SNb NT50c GMT (95% CI)a
mF 2.8E + 07 (2.2E + 07, 3.6E + 07) 2.4E + 07 (1.8E + 07, 3.3E + 07) 4.4E + 04 (2.4E + 04, 7.9E + 04)
sF 2.4E + 07 (1.5E + 07, 3.7E + 07) 7.2E + 06 (5.5E + 06, 9.4E + 06) 3.2E + 04 (1.5E + 04, 6.8E + 04)
mDS-Cav1 3.8E + 07 (2.4E + 07, 5.9E + 07) 4.8E + 06 (2.3E + 06, 1.0E + 07) 7.6E + 03 (2.1E + 03, 2.7E + 04)
sDS-Cav1 1.5E + 07 (1.0E + 07, 2.2E + 07) 2.4E + 06 (2.0E + 06, 3.0E + 06) 4.9E + 03 (1.0E + 03, 2.3E + 04)
RSV F5 1.8E + 07 (9.9E + 06, 3.1E + 07) 5.4E + 06 (2.5E + 06, 1.2E + 07) 1.4E + 04 (9.3E + 03, 2.1E + 04)
RSV F7 2.6E + 07 (1.7E + 07, 3.9E + 07) 9.7E + 06 (6.6E + 06, 1.4E + 07) 1.3E + 04 (5.6E + 03, 4.4E + 04)
RSV F8 1.7E + 07 (1.1E + 07, 2.6E + 07) 4.2E + 06 (2.8E + 06, 6.2E + 06) 2.1E + 04 (9.7E + 03, 4.4 + 04)
DS-Cav1 protein + Adju-Phos ® 1.0E + 06 (1.9E + 05, 5.2E + 06) 2.4E + 05 (4.3E + 04, 1.3E + 06) 2.9E + 03 (2.3E + 02, 3.7E + 04)
Naïve <100 <100 <4
  1. aGMT (95% CI): Geometric mean of the interpolated end point titers and 95% confidence intervals.
  2. bRSV-A-SN: serum neutralization of RSV-A (Long).
  3. cNT50: titer needed to achieve 50% neutralization of RSV-A (Long).